Abingdon Health Notes Announcement by UK-RTC
Abingdon Health Notes Announcement by UK-RTC
on Performance of Rapid Antibody Tests
York, U.K. 16 February 2021: Abingdon Health plc ("the Company"), a leading international developer and manufacturer of high quality and effective rapid tests, welcomes the announcement today by the members of the UK-RTC acknowledging a pre-print publication, funded by Public Health England (PHE), reviewing performance data on rapid antibody tests, including the AbC-19TM Rapid Test.
The study was performed by scientists at PHE, and the Universities of Bristol, Warwick and Cambridge and examined the performance of four lateral flow rapid antibody tests using the same cohort of samples. Although the study remains subject to peer review, it shows that AbC-19TM is highly accurate when tested on samples from individuals previously positive for the virus by PCR and from samples collected pre-pandemic.
· AbC-19TM is within a class of immunoassays which are designed to detect IgG to the full spike of the SARS-CoV-2 virus including neutralising antibodies to the spike protein of the COVID-19 virus. These neutralising antibodies may be produced as part of the body's immune response following COVID-19 infection or post-vaccination; and they not only bind to a virus but they bind in a manner that may block future infection.
· Rapid antibody tests such as the AbC-19TM that measure IgG alone give easily interpretable results and are different to those detecting IgG and IgM on different lines.
Professor Chris Molloy, Chair of the UK-RTC said, "This research on the different use cases for lateral flow antibody tests is welcome. The AbC-19TM test is an important weapon in the global fight against COVID-19. It allows us to see the neutralising IgG antibodies produced in response to infection, or after vaccination".
A detailed commentary based on analysis of the pre-print follows:
· The AbC-19TM rapid antibody test displayed high accuracy (a combination of sensitivity and specificity) on samples from patients who had a self-declared positive PCR and presumed negative samples collected pre-pandemic. The provision of full data sets in the pre-print is useful and allows us to consider other parameters such as accuracy*. When looking at these positive PCR and pre-pandemic negatives, all devices tested had accuracy of >92% with AbC-19TM showing the highest accuracy at 97.3%. Accuracy is an important value which is derived from the number of false positive and false negative results in the population being tested combined with prevalence. No test is 100% accurate - tests with high sensitivity will have a tendency for lower specificity and tests geared towards high specificity may show lower sensitivity. (When calculating accuracy for all devices we used the positive prevalence of the sample set (11.8%) and accuracy will change depending on prevalence).
· The paper stimulates welcome discussion about different types of antibody to SARS-CoV-2 requiring different types of tests. For example, assays detecting antibodies to nucleocapsid protein (NP) will show previous infection whereas assays, such as the AbC-19TM test, detecting IgG to the spike, show the presence of antibodies capable of neutralising the virus and capable of creating immunity. IgG antibodies to the spike include those which neutralise the virus by preventing the spike being able to bind to the ACE2 receptor and enter the human cells.
· Comparison of IgG spike assays to those detecting antibodies to NP on a sample set of unknown status showed lower sensitivity for those which are targeted at anti-spike IgG (84.7% for AbC-19TM). Such side-by-side comparisons of assays with different target analytes are difficult in the absence of reference standards and these differences between tests for different antibody types (e.g. NP versus spike and/or IgM versus IgG) with different use cases are not surprising. Suitable reference standards would aid the continued evaluation of these important tools.
· The AbC-19TM test, detects IgG antibodies which bind to the full trimeric spike protein (which also incorporates the receptor binding domain) and is ideally suited to show the type of antibodies produced to create immunity post infection. These same type of IgG antibodies to the spike protein are generated to produce immunity following vaccination (with use of the devices alongside vaccines requiring further evaluation).
· Rapid antibody tests such as the AbC-19TM that measure IgG alone give very clear results and are different to dual line tests detecting IgG and IgM where IgM may alter interpretation. In our assessment of the results, we have compared complete test results rather than separating results from individual lines for IgM and IgG. This is because, although providing extra information, an end user has to follow the written instructions and interpret all test lines for a dual line test kit.
· The paper highlights the need for discussion on the potential to use of lateral flow devices which detect IgG to the spike protein and how they have potential to be used to monitor for immunity post infection or after vaccination. This will require further evaluation.
This article is available as pre-print via medRxiv:
*Accuracy shows the overall probability that a patient is correctly classified and is calculated as;
Accuracy = Sensitivity × Prevalence + Specificity × (1 − Prevalence)
Abingdon Health plc
Chief Executive Officer
Chief Financial Officer
Sole Broker and Nominated Adviser
Shaun Dobson, Peter Steel,
Tel: +44 (0) 20 7496 3000
Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Tel: +44 (0) 203 709 5700
About Abingdon Health plc
Abingdon Health plc is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
BrainCool AB (publ): BrainCool omstrukturerar för att öka flexibiliteten och planerar byte till Nasdaq First North under Q2 2022
All hänförlig personal, patent, varumärken och rättigheter samt väsentliga avtal överförs. I samband med omstruktureringen kommer Christian Strand, som är ansvarig för affärsutveckling inom BrainCool, utses till tf VD för CoolPrevent AB. VD kommer att bilda en ledningsgrupp med styrelseledamöterna R...
Framtagning av lågtiter blodgrupp 0 helblod: Presentation av resultat vid SABM 2021 (översättning)
Översättning av PM SEP 24, 2021 17:15 CET:Manufacturing of low titer-blood group O whole blood: Presentation of results at the SABM 2021 Annual Meeting Glycorex Transplantation AB (publ.), noterat på NGM Main Regulated Equity, meddelar att Transfusionenheten vid University of R...
Voluntis announces its results for the first half of 2021
Decline in commercial invoicing to€ 1.5 million and IFRS revenue to€ 1.3 million in H1 2021 Significant increase in deferred revenues to€ 11.6 million at 30 June 2021 Significant reduction in operational expenses as part of the strategic roadmap announced in Marc...
Voluntis annonce ses résultats du 1er semestre 2021
Recul des facturations commerciales à 1,5 million d'euros et du chiffre d'affaires IFRS à 1,3 million d'euros au 1er semestre 2021 ; Progression sensible des produits constatés d'avance à 11,6 millions d'euros au 30 juin 2021; Réductio...